Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy

PURPOSE: Few reliable biomarkers for predicting the efficacy of triple therapy (lenvatinib + immune checkpoint inhibitors + transarterial chemoembolization) exist for patients with unresectable hepatocellular carcinoma (uHCC). This study explored the prognostic role of alpha-fetoprotein (AFP) and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Meng-Chao, Wu, Jia-Yi, Wu, Jun-Yi, Lin, Zhong-Tai, Li, Yi-Nan, Zeng, Zhen-Xin, Wei, Shao-Ming, Yan, Mao-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578160/
https://www.ncbi.nlm.nih.gov/pubmed/37850079
http://dx.doi.org/10.2147/JHC.S425674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578160/
https://www.ncbi.nlm.nih.gov/pubmed/37850079
http://dx.doi.org/10.2147/JHC.S425674

Ejemplares similares